Trial reportBone marrow transplantation2005
Autologous hematopoietic stem cell transplantation for autoimmune diseases.
Trial report in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 211 citations in OpenAlex.
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.Bone marrow transplantation · 2012Guideline
- Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties.Frontiers in immunology · 2019Trial
- Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study.Stem cell research & therapy · 2018Trial
- Behçet's syndrome-like features revealing myelodysplastic syndrome withFrontiers in immunology · 2026Article
- Stem cell-based therapy for human diseases.Signal transduction and targeted therapy · 2022Review
- Dysregulated B cell function and disease pathogenesis in systemic sclerosis.Frontiers in immunology · 2022Review
- Remission is not maintained over 2 years with hematopoietic stem cell transplantation for rheumatoid arthritis: A systematic review with meta-analysis.World journal of biological chemistry · 2021Article
- Stem Cell Therapy as a Treatment for Autoimmune Disease-Updates in Lupus, Scleroderma, and Multiple Sclerosis.Current allergy and asthma reports · 2021Review
- Article
- Improved hematopoietic differentiation of mouse embryonic stem cells through manipulation of the RNA binding protein ARS2.Stem cell research · 2020Article
- Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis.Therapeutic advances in neurological disorders · 2020Review
- Autologous haematopoietic stem cell transplantation (AHSCT) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Clinical rheumatology · 2019Article
- Stem Cell-Based Therapies for Multiple Sclerosis: Current Perspectives.Biomedicines · 2019Review
- Feasibility and toxicity of hematopoietic stem cell transplant in multiple sclerosis.Iranian journal of basic medical sciences · 2017Review
- The potential role of adult stem cells in the management of the rheumatic diseases.Therapeutic advances in musculoskeletal disease · 2017Review
- Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.JAMA neurology · 2017Article
- Haematopoietic stem cell transplantation for autoimmune diseases.Nature reviews. Rheumatology · 2017Review
- [Autologous stem cell transplantation in systemic sclerosis].Zeitschrift fur Rheumatologie · 2016Review
- [Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus].Zeitschrift fur Rheumatologie · 2016Review
- Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls.Therapeutic advances in gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 19 institutions in 11 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We have evaluated the toxicity and disease response in 473 patients with severe autoimmune disease treated with autologous HSCT between 1995 and 2003, from 110 centers participating in the European Group for Blood and Marrow Transplantation (EBMT) autoimmune disease working party database. Survival, transplant-related mortality, treatment response and disease progression were assessed. In all, 420 patients (89%; 86+/-4% at 3 years, median follow-up 20 months) were alive, 53 (11%) had died from transplant-related mortality (N=31; 7+/-3% at 3 years) or disease progression (N=22; 9+/-4% at 3 years). Of 370 patients, 299 evaluable for response (81%) showed a treatment response, which was sustained in 213 (71% of responders). Response was associated with disease (P<0.001), was better in patients who received cyclophosphamide during mobilization (relative risk (RR)3.28 (1.57-6.83)) and was worse with increasing age (>40 years, RR0.29 (0.11-0.82)). Disease progression was associated with disease (P<0.001) and conditioning intensity (high intensity, RR1; intermediate intensity, RR1.81 (0.96-3.42)); low intensity, RR2.34 (1.074-5.11)). These data from the collective EBMT experience support the hypothesis that autologous HSCT can alter disease progression in severe autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.